WEST PHARMACEUTICAL SERVICES (WST) Fundamental Analysis & Valuation

NYSE:WST • US9553061055

Current stock price

302.2 USD
-3.96 (-1.29%)
At close:
302.2 USD
0 (0%)
After Hours:

This WST fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. WST Profitability Analysis

1.1 Basic Checks

  • WST had positive earnings in the past year.
  • WST had a positive operating cash flow in the past year.
  • Each year in the past 5 years WST has been profitable.
  • In the past 5 years WST always reported a positive cash flow from operatings.
WST Yearly Net Income VS EBIT VS OCF VS FCFWST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

1.2 Ratios

  • WST has a better Return On Assets (13.21%) than 96.49% of its industry peers.
  • WST's Return On Equity of 18.15% is amongst the best of the industry. WST outperforms 91.23% of its industry peers.
  • WST's Return On Invested Capital of 16.07% is amongst the best of the industry. WST outperforms 94.74% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for WST is above the industry average of 11.48%.
  • The last Return On Invested Capital (16.07%) for WST is above the 3 year average (15.83%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 13.21%
ROE 18.15%
ROIC 16.07%
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.83%
ROIC(5y)17.92%
WST Yearly ROA, ROE, ROICWST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1.3 Margins

  • WST has a Profit Margin of 16.85%. This is amongst the best in the industry. WST outperforms 84.21% of its industry peers.
  • In the last couple of years the Profit Margin of WST has remained more or less at the same level.
  • Looking at the Operating Margin, with a value of 21.24%, WST belongs to the top of the industry, outperforming 87.72% of the companies in the same industry.
  • In the last couple of years the Operating Margin of WST has remained more or less at the same level.
  • Looking at the Gross Margin, with a value of 36.28%, WST is doing worse than 61.40% of the companies in the same industry.
  • WST's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 21.24%
PM (TTM) 16.85%
GM 36.28%
OM growth 3Y-7.75%
OM growth 5Y1.08%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
WST Yearly Profit, Operating, Gross MarginsWST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

8

2. WST Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so WST is still creating some value.
  • Compared to 1 year ago, WST has less shares outstanding
  • WST has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for WST has been reduced compared to a year ago.
WST Yearly Shares OutstandingWST Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
WST Yearly Total Debt VS Total AssetsWST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • An Altman-Z score of 15.02 indicates that WST is not in any danger for bankruptcy at the moment.
  • WST has a Altman-Z score of 15.02. This is amongst the best in the industry. WST outperforms 98.25% of its industry peers.
  • WST has a debt to FCF ratio of 0.45. This is a very positive value and a sign of high solvency as it would only need 0.45 years to pay back of all of its debts.
  • WST's Debt to FCF ratio of 0.45 is amongst the best of the industry. WST outperforms 92.98% of its industry peers.
  • WST has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.07, WST is in the better half of the industry, outperforming 68.42% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 0.45
Altman-Z 15.02
ROIC/WACC1.48
WACC10.86%
WST Yearly LT Debt VS Equity VS FCFWST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 2.71 indicates that WST has no problem at all paying its short term obligations.
  • WST's Current ratio of 2.71 is in line compared to the rest of the industry. WST outperforms 50.88% of its industry peers.
  • A Quick Ratio of 2.04 indicates that WST has no problem at all paying its short term obligations.
  • WST's Quick ratio of 2.04 is in line compared to the rest of the industry. WST outperforms 47.37% of its industry peers.
Industry RankSector Rank
Current Ratio 2.71
Quick Ratio 2.04
WST Yearly Current Assets VS Current LiabilitesWST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

5

3. WST Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 20.03% over the past year.
  • WST shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.94% yearly.
  • WST shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.23%.
  • The Revenue has been growing slightly by 7.44% on average over the past years.
EPS 1Y (TTM)20.03%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%46.9%
Revenue 1Y (TTM)11.23%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%21.05%

3.2 Future

  • The Earnings Per Share is expected to grow by 9.01% on average over the next years. This is quite good.
  • WST is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.95% yearly.
EPS Next Y11.24%
EPS Next 2Y11.04%
EPS Next 3Y11.52%
EPS Next 5Y9.01%
Revenue Next Year6.04%
Revenue Next 2Y6.13%
Revenue Next 3Y6.47%
Revenue Next 5Y7.95%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
WST Yearly Revenue VS EstimatesWST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B
WST Yearly EPS VS EstimatesWST Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2 4 6 8 10

3

4. WST Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 37.92, WST can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Earnings ratio of WST indicates a somewhat cheap valuation: WST is cheaper than 63.16% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.35. WST is valued slightly more expensive when compared to this.
  • The Price/Forward Earnings ratio is 33.62, which means the current valuation is very expensive for WST.
  • Based on the Price/Forward Earnings ratio, WST is valued a bit cheaper than 63.16% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.23. WST is valued rather expensively when compared to this.
Industry RankSector Rank
PE 37.92
Fwd PE 33.62
WST Price Earnings VS Forward Price EarningsWST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • WST's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. WST is cheaper than 61.40% of the companies in the same industry.
  • WST's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 47.56
EV/EBITDA 25.27
WST Per share dataWST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • WST has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)3.37
PEG (5Y)4.24
EPS Next 2Y11.04%
EPS Next 3Y11.52%

6

5. WST Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.33%, WST is not a good candidate for dividend investing.
  • WST's Dividend Yield is rather good when compared to the industry average which is at 0.11. WST pays more dividend than 84.21% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, WST's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.33%

5.2 History

  • The dividend of WST has a limited annual growth rate of 5.48%.
  • WST has been paying a dividend for at least 10 years, so it has a reliable track record.
  • WST has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)5.48%
Div Incr Years33
Div Non Decr Years34
WST Yearly Dividends per shareWST Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • WST pays out 11.39% of its income as dividend. This is a sustainable payout ratio.
  • WST's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP11.39%
EPS Next 2Y11.04%
EPS Next 3Y11.52%
WST Yearly Income VS Free CF VS DividendWST Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
WST Dividend Payout.WST Dividend Payout, showing the Payout Ratio.WST Dividend Payout.PayoutRetained Earnings

WST Fundamentals: All Metrics, Ratios and Statistics

WEST PHARMACEUTICAL SERVICES

NYSE:WST (4/27/2026, 5:14:30 PM)

After market: 302.2 0 (0%)

302.2

-3.96 (-1.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)04-23
Earnings (Next)07-22
Inst Owners97.62%
Inst Owner Change-0.55%
Ins Owners0.29%
Ins Owner Change0.38%
Market Cap21.78B
Revenue(TTM)3.22B
Net Income(TTM)542.70M
Analysts80.87
Price Target328.99 (8.86%)
Short Float %4.08%
Short Ratio3.06
Dividend
Industry RankSector Rank
Dividend Yield 0.33%
Yearly Dividend0.85
Dividend Growth(5Y)5.48%
DP11.39%
Div Incr Years33
Div Non Decr Years34
Ex-Date04-29
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18%
Min EPS beat(2)10.24%
Max EPS beat(2)25.77%
EPS beat(4)4
Avg EPS beat(4)18.02%
Min EPS beat(4)10.24%
Max EPS beat(4)25.77%
EPS beat(8)7
Avg EPS beat(8)12.73%
EPS beat(12)11
Avg EPS beat(12)12.39%
EPS beat(16)14
Avg EPS beat(16)12.42%
Revenue beat(2)2
Avg Revenue beat(2)3.79%
Min Revenue beat(2)0.33%
Max Revenue beat(2)7.25%
Revenue beat(4)4
Avg Revenue beat(4)3.25%
Min Revenue beat(4)0.33%
Max Revenue beat(4)7.25%
Revenue beat(8)7
Avg Revenue beat(8)1.68%
Revenue beat(12)8
Avg Revenue beat(12)0.96%
Revenue beat(16)11
Avg Revenue beat(16)0.86%
PT rev (1m)0%
PT rev (3m)-7.08%
EPS NQ rev (1m)-0.08%
EPS NQ rev (3m)1.61%
EPS NY rev (1m)0.09%
EPS NY rev (3m)3.32%
Revenue NQ rev (1m)0.15%
Revenue NQ rev (3m)2.55%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.21%
Valuation
Industry RankSector Rank
PE 37.92
Fwd PE 33.62
P/S 6.76
P/FCF 47.56
P/OCF 30.45
P/B 7.28
P/tB 7.58
EV/EBITDA 25.27
EPS(TTM)7.97
EY2.64%
EPS(NY)8.99
Fwd EY2.97%
FCF(TTM)6.35
FCFY2.1%
OCF(TTM)9.92
OCFY3.28%
SpS44.69
BVpS41.49
TBVpS39.88
PEG (NY)3.37
PEG (5Y)4.24
Graham Number86.2537 (-71.46%)
Profitability
Industry RankSector Rank
ROA 13.21%
ROE 18.15%
ROCE 19.91%
ROIC 16.07%
ROICexc 18.95%
ROICexgc 19.73%
OM 21.24%
PM (TTM) 16.85%
GM 36.28%
FCFM 14.22%
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.83%
ROIC(5y)17.92%
ROICexc(3y)20.32%
ROICexc(5y)23.97%
ROICexgc(3y)21.34%
ROICexgc(5y)25.37%
ROCE(3y)19.61%
ROCE(5y)22.21%
ROICexgc growth 3Y-13.74%
ROICexgc growth 5Y-3.06%
ROICexc growth 3Y-13.28%
ROICexc growth 5Y-2.17%
OM growth 3Y-7.75%
OM growth 5Y1.08%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
F-Score7
Asset Turnover0.78
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 0.45
Debt/EBITDA 0.24
Cap/Depr 145.7%
Cap/Sales 7.99%
Interest Coverage 250
Cash Conversion 83.1%
Profit Quality 84.39%
Current Ratio 2.71
Quick Ratio 2.04
Altman-Z 15.02
F-Score7
WACC10.86%
ROIC/WACC1.48
Cap/Depr(3y)224.35%
Cap/Depr(5y)223.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)10.68%
Profit Quality(3y)73.64%
Profit Quality(5y)69.18%
High Growth Momentum
Growth
EPS 1Y (TTM)20.03%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%46.9%
EPS Next Y11.24%
EPS Next 2Y11.04%
EPS Next 3Y11.52%
EPS Next 5Y9.01%
Revenue 1Y (TTM)11.23%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%21.05%
Revenue Next Year6.04%
Revenue Next 2Y6.13%
Revenue Next 3Y6.47%
Revenue Next 5Y7.95%
EBIT growth 1Y16.64%
EBIT growth 3Y-5.8%
EBIT growth 5Y8.6%
EBIT Next Year43.62%
EBIT Next 3Y20.28%
EBIT Next 5Y16.28%
FCF growth 1Y18.62%
FCF growth 3Y2.19%
FCF growth 5Y9.48%
OCF growth 1Y-5.46%
OCF growth 3Y1.4%
OCF growth 5Y9.82%

WEST PHARMACEUTICAL SERVICES / WST Fundamental Analysis FAQ

What is the fundamental rating for WST stock?

ChartMill assigns a fundamental rating of 7 / 10 to WST.


What is the valuation status for WST stock?

ChartMill assigns a valuation rating of 3 / 10 to WEST PHARMACEUTICAL SERVICES (WST). This can be considered as Overvalued.


How profitable is WEST PHARMACEUTICAL SERVICES (WST) stock?

WEST PHARMACEUTICAL SERVICES (WST) has a profitability rating of 8 / 10.


What is the financial health of WEST PHARMACEUTICAL SERVICES (WST) stock?

The financial health rating of WEST PHARMACEUTICAL SERVICES (WST) is 8 / 10.


What is the expected EPS growth for WEST PHARMACEUTICAL SERVICES (WST) stock?

The Earnings per Share (EPS) of WEST PHARMACEUTICAL SERVICES (WST) is expected to grow by 11.24% in the next year.